Definitive Healthcare Corp.
Definitive Healthcare provides healthcare data and analytics through a software-as-a-service platform. Its products give customers information on healthcare organizations, providers, services, medical and scientific experts, claims, and consumers, which they use for product development, market planning, sales and marketing, and other commercial decisions. The company serves life sciences businesses, including biopharmaceutical and medical device companies; healthcare providers such as hospitals and health systems; and diversified healthcare organizations, including health information technology companies, staffing firms, financial institutions, and marketing agencies. Definitive Healthcare combines data from thousands of sources with analytics and data science to create intelligence and tools for identifying markets, planning sales efforts, and reaching decision-makers. Customers access its data products by subscription, and the company generates substantially all its revenue from subscription fees. Definitive Healthcare is headquartered in Framingham, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $DH in the last 30 days.
See all $DH insider activity →Definitive Healthcare (DH) reported Q3 EPS of $0.06, beating estimates by $0.02, with revenue at $54.65M, slightly above expectations. The stock is up 58.37% in 3 months but down 61.43% year-over-year. InvestingPro rates its financial health as 'good performance'.
Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter 2026 Third Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (November 5, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),
Definitive Healthcare (DH) appointed Rebecca Marani as Chief Product Officer and Srinivas Attipalli as SVP, Head of AI and Data. The company's AI-powered intelligence platform early adopter program is underway, with initial findings to be shared at HLTH this month. According to DH, these appointments support its AI strategy announced earlier this year.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning DH (Definitive Healthcare Corp.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.
Recent DH coverage spans earnings, financial news and regulation.
Earnings beat may generate modest buying pressure.
Earnings miss on revenue and loss may pressure the stock.
Management changes tied to an AI and data platform rollout could shift investor expectations for product execution and customer adoption timing.
The compliance announcement may modestly improve investor sentiment by reducing regulatory risk.
Potential delisting creates upside for shareholders.
AlphAI scores every news story that mentions DH with an AI model for sentiment and relevance, and aggregates insider trades from Definitive Healthcare Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Definitive Healthcare (DH) reported Q3 EPS of $0.06, beating estimates by $0.02, with revenue at $54.65M, slightly above expectations. The stock is up 58.37% in 3 months but down 61.43% year-over-year. InvestingPro rates its financial health as 'good performance'.
Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter 2026 Third Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (November 5, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),
Definitive Healthcare (DH) appointed Rebecca Marani as Chief Product Officer and Srinivas Attipalli as SVP, Head of AI and Data. The company's AI-powered intelligence platform early adopter program is underway, with initial findings to be shared at HLTH this month. According to DH, these appointments support its AI strategy announced earlier this year.
Definitive Healthcare (DH) joined the Network Advertising Initiative (NAI) to strengthen data privacy compliance. The company aims to assure customers of its adherence to federal and state data protection requirements. NAI's Vice President of Public Policy highlighted Definitive Healthcare's commitment to responsible data handling.
Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.
Definitive Healthcare Corp. (DH) received a non-binding take-private proposal from Advent International for $1.02 per share. The offer is subject to review by a special committee and requires founder Jason Krantz's equity rollover. No binding agreement exists yet, and Advent may withdraw or modify the proposal.
Definitive Healthcare Corp. (DH) named Clay Ritchey as CEO and board member, effective September 8. Ritchey succeeds Kevin Coop, who left on August 31, 2026. Ritchey previously led Verato, Evariant, and other healthcare firms. DH shares rose 13.04% in pre-market trading.
Definitive Healthcare (NASDAQ:DH) shares rose 13% after Advent International offered to buy the company for $1.02 per share, a 36% premium over its 60-day average. The deal requires approval from a special committee and Jason Krantz's stock rollover. Definitive Healthcare also appointed Clay Ritchey as CEO, replacing Kevin Coop.
Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Definitive Healthcare Appoints Clay Ritchey as CEO Mr. Ritchey brings more than 25 years of deep healthcare expertise to Definitive Framingham, MA (September 2, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthca
Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.
